Key Developments: Novogen Ltd (NVGN.PH)
4.87USD
29 Apr 2013
$0.21 (+4.51%)
$4.66
$4.87
$4.87
$4.87
1,000
--
--
--
Latest Key Developments (Source: Significant Developments)
Novogen Ltd Issues New Ordinary Shares
Novogen Ltd announced that it has issued 14,425,150 ordinary shares at an issue price of AUD 0.166 per share. The shares are issued to fund Phase 1 of CS-6 program; running program seeking new drugs; corporate costs and working capital as approved by shareholders at General Meeting held on April 19, 2013. Full Article
Novogen Ltd Announces Share Purchase Plan
Novogen Ltd announced its Share Purchase Plan (SPP), which gives eligible shareholders the opportunity to purchase up to AUD 15,000 worth of Novogen's ordinary shares without incurring brokerage or transaction costs. Only Australian and New Zealand investors who were recorded on the share register as shareholders on the record date of April 16, 2013 (record date) are entitled to participate in the SPP offer. Full Article
Novogen Ltd Signs Memorandum of Understanding With The Ingham Institute
Novogen Ltd announced the signing of a Memorandum of Understanding with The Ingham Institute in a cooperative venture to develop the new class of super-benzopyran molecules as anti-cancer drugs intended to offer cancer therapy. The global collaborative network of which The Ingham Institute is part will participate in identifying and developing this new approach to cancer therapy. Full Article
Novogen Ltd Issues Ordinary Shares For Acquisition Of Triaxial Pharmaceuticals Pty Ltd
Novogen Ltd announced the issuance of 13,600,000 ordinary shares as part of consideration for acquisition of Triaxial Pharmaceuticals Pty Ltd shares. Full Article
Novogen Ltd Announces Filing Of Key Patent Application
Novogen Ltd announced that the filing of a provisional patent application covering the technology associated with the manufacture and use of it new class of molecules referred to as super-benzopyrans. The invention is based on technology that Novogen acquired when it purchased Triaxial Pharmaceuticals Pty Ltd on Dec 7, 2012. Triaxial had developed a manufacturing process that involved chemically ‘bending’ molecules to allow the insertion of atoms not previously possible. Provisional patent application No 2012905600 covers the three cornerstones of patent protection around Novogen’s initial family of super-benzopyrans: method of manufacture, method of use, and composition of matter. Full Article
Novogen Ltd's Chairman Of The Board Resigns
Novogen Ltd announced that Mr. William D. Rueckert has resigned as Chairman of the Board of the Company. Full Article
Novogen Ltd Completes Acquisition Of Triaxial Pharmaceuticals
Novogen Ltd announced the completion of the acquisition of 10% of the outstanading shares of Triaxial Pharmaceuticals Pty Ltd, The total purchase price of AUD 1.885 million consisted of a comabination of 15.4 million NOvogen shares and a AUD 15 million loan payable to the Triaxial shareholders. Full Article
Novogen Ltd To Acquire Triaxial Pharmaceuticals Pty Ltd
Novogen Ltd announced that it has signed a term sheet in relation to the proposed acquisition of all of the shares of Triaxial Pharmaceuticals Pty Ltd for AUD 1.88 million in a combination of the Company's ordinary shares and debt based on the achievement of certain clinical milestones. Full Article
Novogen Ltd Announces Termination Of Merger Agreement With Kai Medical
Novogen Ltd announced the termination of its previously announced merger agreement with Kai Medical. Under the terms of the merger agreement entered into by the companies, the merger agreement shall forthwith become void and have no effect without any liability or obligation on the part of Novogen or Kai. The details of the transaction made it impossible to insure the continued listing of Novogen's securities on the ASX and Nasdaq markets. In making the decision, the Novogen Board agreed that it is an imperative that it maintains the listings and liquidity in the Company's shares. Full Article
Novogen Ltd Announces No Dividend For FY 2012
Novogen Ltd announced that the Directors of Novogen Limited do not recommend the payment of a dividend for the year ended June 30, 2012. Full Article
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
